Exenatide and pramlintide: New glucose-lowering agents for treating diabetes mellitus

Byron J. Hoogwerf, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail hoogweb@ccf.org

The author has indicated that he serves on an advisory committee to develop educational materials for the Amylin/Lilly Synergy partnership.

Byron J. Hoogwerf, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail hoogweb@ccf.org

The author has indicated that he serves on an advisory committee to develop educational materials for the Amylin/Lilly Synergy partnership.

Byron J. Hoogwerf, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Address: Byron J. Hoogwerf, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail hoogweb@ccf.org

The author has indicated that he serves on an advisory committee to develop educational materials for the Amylin/Lilly Synergy partnership.